Remembering Mark Morgan

We'd like to give a heartfelt salute and heavenly birthday wishes to our co-founder, Mark Morgan. Mark was a man like no other. He was compassionate, giving, caring to EVERYONE! People who came in contact with him, young or old, were drawn to his free spirit and his impeccable artistic and mechanical skills. To know him was truly to love him. Mark was also a true fighter and although stricken with Cystic Fibrosis, he left no stone unturned. He did not allow CF to hinder whatever he had set out to do; whether it be woodworking, working on race cars, or putting up a canopy for his mom. He was unstoppable. He had a heart of pure gold and he was a great loss to those who knew him and his family.

In his honor, we are asking if you could make a donation of any kind to the organization that he co-founded with his cousin Russ Morgan,

It was Mark's desire for this nonprofit org to be able to give to others that are enduring the relentless affects of Cystic Fibrosis. His family and Board Members of W4CF are carrying that mission out for him.

Happy Heavenly Birthday Mark! You will ALWAYS be in our hearts.💜💜💜💜


2018 Coming to an End

Fall is fastly approaching and as 2018 comes to an end, we would like to give a big, warm heartfelt THANK YOU to everyone who has been moved to help us. Through donations, a successful fundraiser and our continued support from Fuchs Motorsports, we are all helping to raise more awareness to Cystic Fibrosis. We still have much more work to do, but with your continued support, we know we will get there. So again, from our family to yours…THANK YOU!

Hope For Those Affected By Pseudomonas Aeruginosa Bacterium

Cystic Fibrosis Hope: Scientists Target Switch in Fatal Antibiotic-Resistant Superbug

Scientists have found a new way to target an antibiotic-resistant superbug that thrives in patients with severe respiratory diseases such as cystic fibrosis.

The Pseudomonas aeruginosa bacterium exploits the oxygen-limited conditions in the lungs of respiratory patients.

The infection promotes an inflammatory response that then destroys lung tissue.

It is responsible for six percent of health-related infections in NHS patients and is a major cause of death in people with cystic fibrosis.


However, researchers at the University of Cambridge have found a switch that turns on aggressive infection in the superbug, giving hope that new ways to target the bacterium can be found.

The study is published in the Royal Society’s journal Open Biology.

One in every 2,500 babies born in the UK will have cystic fibrosis. Over 9,000 people in the UK are currently living with the condition, which clogs the lungs with a sticky mucus.

Lead investigator Martin Welch said: “This is particularly important because the bug is strongly associated with infections in patients with severe respiratory disease; most famously patients with cystic fibrosis – many of whom eventually succumb to P. aeruginosa infections.

“Counter-intuitively, the lung tissue of such patients is oxygen-limited, so this could trigger the pathway.”

New treatments

When P. aeruginosa encounters low-oxygen conditions, it triggers a mechanism called the Type III Secretion System, which injects toxins directly from the bacterium into the host cell. They then subvert their function, leading to cell death.

The switch identified has been named the glyoxylate shunt, which is activated in low-oxygen conditions. This results in an enzyme called isocitrate lyase (ICL) being expressed and activation of the T3SS.

When there is no ILC expression, the T3SS is not turned on and the deadly toxins are not injected.

Dr Welch said: “The mechanism by which ICL impacts on the T3SS involves a previously unrecognised regulatory pathway.

“Crucially we found that this regulatory pathway also affected the formation of antibiotic-resistant biofilms by P. aeruginosa.

“This is important because biofilm formation is known to play an important role in the pathology of cystic fibrosis-associated infections. Our study therefore opens up new potential avenues for the development of novel antibacterial therapeutic interventions.”

Janet Allen, director of Research at the Cystic Fibrosis Trust said: “Many people with Cystic Fibrosis will develop Pseudomonas aeruginosa during their lives and it can cause chronic infection, which reduces lung function and therefore life expectancy.

“The Cystic Fibrosis Trust welcomes this research from the University of Cambridge which helps us to understand more about why this bacterium thrives in the lungs of those with cystic fibrosis, and could in the future lead to more treatments.”

MediCarePlus article from 07/14/2016